테라노스틱스 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Theranostics Market size is expected to reach USD 11.15 Billion in 2034 from USD 3.40 Billion (2025) growing at a CAGR of 14.11% during 2026-2034.

The global theranostics market is growing rapidly as personalized medicine becomes increasingly important in modern healthcare. Theranostics combines therapeutic and diagnostic technologies to identify diseases and deliver targeted treatments simultaneously. This approach allows healthcare professionals to diagnose conditions more accurately and tailor treatments to individual patients, improving treatment outcomes and reducing side effects.

One of the major drivers of the market is the rising prevalence of chronic diseases such as cancer and cardiovascular disorders. Theranostics plays a significant role in oncology by enabling early detection of tumors and targeted drug delivery. Advances in molecular imaging, nuclear medicine, and biomarker research are also supporting the development of innovative theranostic solutions for various medical conditions.

Looking ahead, the theranostics market is expected to grow significantly as healthcare systems move toward precision medicine. Pharmaceutical and biotechnology companies are investing heavily in research and development to create new theranostic drugs and diagnostic tools. Increasing healthcare investments and growing awareness about personalized treatment approaches will continue to drive the adoption of theranostics in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Diagnostic Imaging
• Radiopharmaceuticals
• IVD/Biomarker Screeening
• Software And Services

By Application

• Prostate Cancer
• Bone Metastasis
• Neuroendocrine Tumors
• Lymphoma
• Cardiovascular Diseases
• Other

By End-Use

• Hospitals
• Diagnostics Centers
• Specialty Clinics
• Other

COMPANIES PROFILED

• Bayer AG, Beckman Coulter Inc, Cardinal Health Inc, Canon Medical Systems Corporation, Curium, F Hoffmann La Roche Ltd, GE HealthCare Technologies Inc, Koninklijke Philips NV, Lantheus Holdings Inc, Siemens Healthnieers AG, Thermo Fisher Scientific Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL THERANOSTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Diagnostic Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Radiopharmaceuticals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. IVD/Biomarker Screeening Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Software And Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL THERANOSTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Bone Metastasis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Neuroendocrine Tumors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL THERANOSTICS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostics Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL THERANOSTICS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Application
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Application
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Application
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Application
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Application
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL THERANOSTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Bayer AG
  • 9.2.2 Beckman Coulter Inc
  • 9.2.3 Cardinal Health Inc
  • 9.2.4 Canon Medical Systems Corporation
  • 9.2.5 Curium
  • 9.2.6 F. Hoffmann La Roche Ltd
  • 9.2.7 GE HealthCare Technologies Inc
  • 9.2.8 Koninklijke Philips N.V
  • 9.2.9 Lantheus Holdings Inc
  • 9.2.10 Siemens Healthnieers AG
  • 9.2.11 Thermo Fisher Scientific Inc